第一太平(00142.HK)中期純利升79.92%至1.81億美元 中期息9港仙
格隆匯8月25日丨第一太平(00142.HK)公佈中期業績,截至2021年6月30日止6個月,公司營業額42.26億美元,同比增長22.93%;公司擁有人應占溢利1.81億美元,同比增長79.92%;每股基本盈利4.18美仙,擬派中期股息每股9.00港仙。
於20021年上半年,由於大部份營運公司(尤其是Indofood、PLDT及MPIC)的貢獻增加,第一太平業績表現強勁,來自營運公司的貢獻上升26%至2.49億美元。縱使2019冠狀病毒病疫情的挑戰持續,集團管理有方的核心業務的增長勢頭持續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.